If signed into law, H.R. 2212 would increase competition in the prescription drug industry by encouraging generic and biosimilar drug manufacturers to introduce their products to the market more quickly.
Representative Tom Marino (PA-10) introduced H.R. 2212 April 28,2017. It has since been referred to the Subcommittee on Health.
Learn more about H.R.2212 here.